BrainsWay is an industry leader in the field of transcranial magnetic stimulation (TMS). BrainsWayâs flagship Deep TMS technology is a non-invasive, well-tolerated outpatient treatment, clinically proven to treat psychiatric and neurological conditions. BrainsWay has received FDA-clearance for both major depression (MDD) and obsessive compulsive disorder (OCD- De Novo) and is developing more applications outside of the US. The company also has approval in Japan and other Asian countries. BrainsWay continues to push the TMS envelope with multiple clinical studies and further research into novel indications. BrainsWay has an experienced business and development management team, as well as the backing of key scientific opinion leaders. BrainsWay was founded in 2003 and began trading on the NASDAQ in 2019 under the symbol BWAY. Source
No articles found.
IDEAYA is an oncology-focused precision medicine company committed to the discover...
IDEAYA is an oncology-focused precision medicin...
SmileDirectClub was founded on one simple belief: everyone deserves a smile they l...
SmileDirectClub was founded on one simple belie...
Aurinia is a late clinical stage biopharmaceutical company focused on developing a...
Aurinia is a late clinical stage biopharmaceuti...
BioTelemetry, Inc. is the leading remote medical technology company focused on the...
BioTelemetry, Inc. is the leading remote medica...
IMAC Holdings, Inc. owns or manages IMAC Regeneration Centers, which combine life ...
IMAC Holdings, Inc. owns or manages IMAC Regene...
InMode Ltd. (Nasdaq: INMD) is a leading global provider of innovative medical tech...
InMode Ltd. (Nasdaq: INMD) is a leading global ...
Following two acquisitions of Creagh Medical and NorMedix â recognized innovator...
Following two acquisitions of Creagh Medical an...
Join the National Investor Network and get the latest information with your interests in mind.